Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...

Living with transthyretin cardiac amyloidosis (ATTR-CM) can make everyday movement difficult. When you have this rare heart condition, blood protein deposits form amyloid fibrils that cause the heart ...

Featured topics and Editors' Picks from all of ACC's JACC Journals. Vutrisiran and All-Cause Mortality, Prognostic Implication of sTTR Levels in ATTR-CM Studies exploring the association between ...

A new ACC Concise Clinical Guidance (CCG) report on "Transthyretin Cardiac Amyloidosis Evaluation and Management" provides updated strategies and best practices for clinicians, taking into account ...

The phase III trial studying CRISPR gene editing therapy for transthyretin amyloidosis (ATTR) was paused for safety due to an alarming case of poor liver function in one patient, Intellia Therapeutics ...

"In a decade, I hope Jackson will be a living testament to innovation and growth. It will be a place defined by its ...

There was an error while loading. Please reload this page. You are tasked with writing JavaScript code for a data processing tool. This tool will handle user input ...

The chancellor says "the world has thrown even more challenges our way" - Tory leader Kemi Badenoch calls the pre-Budget ...